Zobrazeno 1 - 10
of 233
pro vyhledávání: '"Masafumi, Kurosumi"'
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 15, Iss , Pp 100311- (2024)
We report a case of human epidermal growth factor receptor 2 (HER2)-positive Stage IV breast cancer with metastatic lung cancer treated with cryoablation as a first-line treatment. The patient, a 34-year-old woman who voluntarily screened for breast
Externí odkaz:
https://doaj.org/article/1a31378bf0524a73a93dceadcb71b95b
Autor:
Sasagu Kurozumi, Kyoichi Kaira, Hiroshi Matsumoto, Masafumi Kurosumi, Takehiko Yokobori, Yoshikatsu Kanai, Chikako Sekine, Chikako Honda, Ayaka Katayama, Mio Furuya, Sho Shiino, Takaya Makiguchi, Nigel P. Mongan, Emad A. Rakha, Tetsunari Oyama, Takaaki Fujii, Ken Shirabe, Jun Horiguchi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract L-type amino acid transporter 1 (LAT1), also referred to as SLC7A5, is believed to regulate tumor metabolism and be associated with tumor proliferation. In invasive breast cancer, we clinicopathologically investigated the utility of LAT1 exp
Externí odkaz:
https://doaj.org/article/4daa3a3afb8940298b1d057e671dbd12
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). Methods Pa
Externí odkaz:
https://doaj.org/article/6f69a6a4de23498b91dd4a4577d0b1f8
Autor:
Sasagu Kurozumi, Hiroshi Matsumoto, Yuji Hayashi, Katsunori Tozuka, Kenichi Inoue, Jun Horiguchi, Izumi Takeyoshi, Tetsunari Oyama, Masafumi Kurosumi
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study
Externí odkaz:
https://doaj.org/article/d86460adea0b4500860973e0978198ae
Autor:
Sasagu Kurozumi, Yuri Yamaguchi, Hiroshi Matsumoto, Masafumi Kurosumi, Shin-Ichi Hayashi, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Kenichi Inoue
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217279 (2019)
In this study, we investigated the relationships of pathological response after neoadjuvant chemo-endocrine therapy with alterations in the Ki67 labeling index (LI), expression of cyclin D1 (CCND1) and progesterone receptor (PgR), and estrogen recept
Externí odkaz:
https://doaj.org/article/c07a19ae07364779b657a6098f518a48
Autor:
TATSUYUKI GOHNO, TORU HANAMURA, MASAFUMI KUROSUMI, HIROYUKI TAKEI, YURI YAMAGUCHI, SHIN-ICHI HAYASHI
Publikováno v:
Anticancer Research. 42:759-766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3607986ea1b917e7772f05db283100d5
https://doi.org/10.21873/anticanres.15534
https://doi.org/10.21873/anticanres.15534
Autor:
Sasagu Kurozumi, Hiroshi Matsumoto, Kenichi Inoue, Katsunori Tozuka, Yuji Hayashi, Masafumi Kurosumi, Tetsunari Oyama, Takaaki Fujii, Jun Horiguchi, Hiroyuki Kuwano
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201846 (2018)
The preoperative endocrine prognostic index (PEPI) predicts survival after neoadjuvant endocrine therapy (NAE) using aromatase inhibitors (AIs) for women with postmenopausal estrogen receptor (ER)-positive breast cancer irrespective of the human epid
Externí odkaz:
https://doaj.org/article/bfbfe1de57514447a1e89925d948721a
Autor:
Shinji Ohno, Futoshi Akiyama, Akihiko Shimomura, Shintaro Takao, Toru Watanabe, Shozo Ohsumi, Yasuo Ohashi, Hitoshi Tsuda, Shigehira Saji, Nobuaki Sato, Masafumi Kurosumi, Hideo Inaji, Yutaka Tokuda, Norikazu Masuda
Publikováno v:
Breast Cancer Research and Treatment
Purpose To evaluate the efficacies of cyclophosphamide, methotrexate, and fluorouracil (CMF) and tegafur–uracil (UFT) as adjuvant therapy in patients with resected stage I–IIIA breast cancer by immunohistochemistry (IHC)-based subtype and to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0511c678eeb71553cb9a60ff5d801a72
http://europepmc.org/articles/PMC7940338
http://europepmc.org/articles/PMC7940338
Autor:
Hitoshi Tsuda, Futoshi Akiyama, Toru Watanabe, Yasuo Ohashi, Akihiko Shimomura, Nobuaki Sato, Hideo Inaji, Shozo Ohsumi, Shinji Ohno, Shigehira Saji, Yutaka Tokuda, Masafumi Kurosumi, Norikazu Masuda, Shintaro Takao
Publikováno v:
Cancer Research. 80:P2-14
Background: Two randomized controlled trials comparing the efficacy of oral tegafur-uracil (UFT) (2 years) with that of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) (6 courses) were conducted in patients with resected early breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5996a6f5fd0040f782fef51ae3e56da3
https://doi.org/10.1158/1538-7445.sabcs19-p2-14-17
https://doi.org/10.1158/1538-7445.sabcs19-p2-14-17
Autor:
Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, Shinji Ohno, Shigehira Saji, Norikazu Masuda, Akihiko Shimomura, Nobuaki Sato, Shintaro Takao, Shozo Ohsumi, Yutaka Tokuda, Hideo Inaji, Toru Watanabe
Publikováno v:
Breast cancer (Tokyo, Japan). 29(4)
Background This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institutional randomized N·SAS-BC 01
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a19ba89019cd131d048049127a72c6a
https://pubmed.ncbi.nlm.nih.gov/35499664
https://pubmed.ncbi.nlm.nih.gov/35499664